Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Eptastigmine (heptyl‐physostigmine tartrate) is a carbamate derivative of physostigmine in which the carbamoylmethyl group in position 5 of the side chain has been substituted with a carbamoylheptyl group.In vitro and ex vivo results suggest that eptastigmine has a long‐lasting reversible brain cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) inhibitory effect. When administered in vivo to rodents by various routes, eptastigmine inhibits cerebral acetylcholinesterases (AChE) and increases acetylcholine (Ach) brain levels by 2500–3000%, depending on the dose. This effect leads to an improvement in the cerebral blood flow in the ischemic brain, excitatory and inhibitory effects on the gastrointestinal tract and to a protection from acute soman and diisopropylflu‐orophosphate intoxication. Eptastigmine, by either acute or chronic administration, has been found to have memory enhancing effects in different species of normal, aged and lesioned animals. It also restored to normal the age‐related increase of EEG power without affecting spontaneous motor activity. Clinical investigations on more than 1500 patients with Alzheimer's disease demonstrated that eptastigmine significantly improved cognitive performance (as assessed by the cognitive subscale of the Alzheimer's Disease Assessment Scale) as compared with placebo. This improvement was most evident in patients with more severe cognitive impairment at the baseline. The relationship between patient performance and average steady‐state AChE inhibition was described by an inverted U‐shaped dose‐response curve. Pharmacokinetic studies have revealed that after oral administration eptastigmine is rapidly distributed to the tissues and readily enters the CNS, where it can be expected to inhibit AChE for a prolonged period. Eptastigmine is generally well tolerated and the majority of adverse events (cholinergic) were mild to moderate in intensity. However, the adverse hematologic (granulocytopenia) effects reported in two studies have resulted in the suspension of further clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winslow, J. T., & Camacho, F. (1995) · Psychopharmacology · doi:10.1007/bf02245626 · Cited by 156
Cited by
Ramsay, R., & Tipton, K. (2017) · Molecules · doi:10.3390/molecules22071192 · Cited by 258
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
“Of the other compounds under preclinical and clinical investigation for many years, the clinical efficacy of heptylphysostigmine (eptastigmine) was demonstrated [12], but adverse hematologic (granulocytopenia) effects reported in two studies resulted in the suspension of further clinical trials [13].”
BackgroundOld and new acetylcholinesterase inhibitors for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216972 · Cited by 117
“Six clinical trials have been carried out on more than 1500 patients with AD (see Braida and Sala [3] for review).”
BackgroundShen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
Metadata
- Authors
- Braida, D., & Sala, M.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 7
- Issue
- 4
- Pages
- 369-386
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2078548800
- Cited by
- 42
- References
- 1
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies. https://app.cochat.ai/papers/10.1111/j.1527-3458.2001.tb00205.x
- The paper
- Braida, D., & Sala, M. (2001). Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2001.tb00205.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.